Trials / Completed
CompletedNCT03444766
Study of Nivolumab for Advanced Cancers in India
Safety Study of Nivolumab for Selected Advanced Malignancies in India
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 100 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a study of nivolumab in participants with advanced Non-Small Cell Lung Cancer or Kidney Cancer in India.
Conditions
- Non-Small Cell Lung Cancer (NSCLC)
- Non-Small-Cell Lung Carcinoma
- Nonsmall Cell Lung Cancer
- Kidney Cancer
- Kidney Neoplasms
- Renal Cancer
- Renal Neoplasms
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Nivolumab | specified dose on specified days |
Timeline
- Start date
- 2018-03-06
- Primary completion
- 2019-07-17
- Completion
- 2019-07-17
- First posted
- 2018-02-23
- Last updated
- 2020-12-04
- Results posted
- 2020-12-04
Locations
9 sites across 1 country: India
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03444766. Inclusion in this directory is not an endorsement.